| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1933-NSCLC, Stg II-III, RT + Atezo | 1 | Y | 1 Hypofractionated Radiotherapy | 47 | 47 | 6 | 2 | 0 | 0 | 0 | 01/13/2021 | 116 | 36 |
| 47 | 6 | 2 | 0 | 0 | 0 | |||||||||
| 2 | Y | 2 Atezolizumab | 38 | 7 | 4 | 2 | 0 | 0 | 01/13/2021 | |||||
| 38 | 7 | 4 | 2 | 0 | 0 | |||||||||
| S2409-ESCLC, Durvalumab +/- Biomarker Directed Tx | 1 | Y | 0 Screening & Cohort Assignment | 900 | 7 | 7 | 7 | 7 | 3 | 2 | 11/06/2025 | 152 | 43 | |
| 7 | 7 | 7 | 7 | 3 | 2 | |||||||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | 1 | Y | 1 Durvalumab | 306 | 3 | 3 | 1 | 1 | 0 | 0 | 04/01/2025 | 276 | 77 | |
| 2 Surveillance | 2 | 2 | 2 | 1 | 0 | 0 | ||||||||
| 5 | 5 | 3 | 2 | 0 | 0 | |||||||||
| Yes | A081801-ALCHEMIST4, ALK and EGFR negative, Chemo-IO | 1 | E | Total Registrations | 101 | 14 | 9 | 3 | 1 | 0 | 10/20/2020 | 417 | 164 | |
| 101 | 14 | 9 | 3 | 1 | 0 | |||||||||
| EA5162-NSCLC,StgIV/IIB,EGFR exon20 insertion,AZD9291 | 1 | E | Total Registrations | 4 | 3 | 0 | 0 | 0 | 0 | 08/23/2023 | 98 | 35 | ||
| 4 | 3 | 0 | 0 | 0 | 0 | |||||||||
| EA5182-NSCLC, Met EGFR mut, AZD9291+Beva vs AZD9291 | 1 | E | Total Registrations | 25 | 4 | 1 | 0 | 0 | 0 | 04/28/2021 | 220 | 82 | ||
| 25 | 4 | 1 | 0 | 0 | 0 | |||||||||
| EA5221-Lung, Advanced NSCLC, ChemoImmuno/Immuno | 1 | E | Total Registrations | 5 | 4 | 2 | 1 | 0 | 0 | 08/07/2024 | 210 | 80 | ||
| 5 | 4 | 2 | 1 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 4 | 3 | 2 | 1 | 0 | 0 | 08/07/2024 | |||||
| 4 | 3 | 2 | 1 | 0 | 0 | |||||||||
| NRGLU008-Lung NSCL, StgII-III, StereoBodyRad/MedChemo | 1 | E | Total Registrations | 5 | 3 | 2 | 0 | 0 | 0 | 01/26/2024 | 316 | 127 | ||
| 5 | 3 | 2 | 0 | 0 | 0 | |||||||||
| No | S2402-NSCLC, All Stg, Periop Vs Adj Tx | 1 | E | Total Registrations | 6 | 6 | 2 | 2 | 2 | 0 | 04/22/2025 | 139 | 61 | |
| 6 | 6 | 2 | 2 | 2 | 0 | |||||||||
| A082002-Lung, Adv, Systemic Tx +/- SBRT | 1 | E | Total Registrations | 4 | 0 | 0 | 0 | 0 | 0 | 10/12/2022 | 258 | 74 | ||
| 4 | 0 | 0 | 0 | 0 | 0 | |||||||||
| EA5231-Lung, Stg II-IIIB, CheckBlock | 0 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 12/15/2025 | 4 | 1 | ||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| 1 | E | Total Registrations | 1 | 1 | 1 | 1 | 1 | 0 | 12/15/2025 | |||||
| 1 | 1 | 1 | 1 | 1 | 0 | |||||||||
| Study | Registration/Phase | Open Date | # of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|
| S2409 ESCLC, Durvalumab +/- Biomarker Directed Tx | 2 Randomization | 08-Sep-25 | 152 | 43 |